113.00 -0.43 (-0.38%)
After hours: 5:28PM EDT
|Bid||108.59 x 800|
|Ask||114.00 x 1400|
|Day's Range||110.38 - 113.91|
|52 Week Range||49.03 - 142.97|
|Beta (5Y Monthly)||0.76|
|PE Ratio (TTM)||18.64|
|Forward Dividend & Yield||4.52 (4.24%)|
|Ex-Dividend Date||Mar. 30, 2020|
|1y Target Est||N/A|
Medifast (MED) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Top Ranked Momentum Stocks to Buy for June 3rd
Top Ranked Income Stocks to Buy for June 1st
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Those holding Medifast (NYSE:MED) shares must be pleased that the share price has rebounded 38% in the last thirty...
On the call with me today are Dan Chard, chief executive officer, and Joe Kelleman, interim chief financial officer. If you've not received the release, it is available on the investor relations portion of Medifast's website at www.medifastinc.com. Before we begin, we'd like to remind everyone that the prepared remarks contain forward-looking statements and management may make additional forward-looking statements in response to your questions.
Medifast (MED) delivered earnings and revenue surprises of 46.21% and 10.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?